EQL Pharma: Mellozzan® (melatonin) launched in the UK
EQL's key product Mellozzan® (tablets) has now been launched in the UK by our partner Medice. Medice specialise in ADHD and have previously launched Mellozzan® successfully in Germany, among other countries. Unlike many other countries in Europe, there is already a growing use of melatonin to treat children with ADHD and sleep problems in the UK. The melatonin tablet market had a turnover of around £10.8 million in 2024, with a volume growth of 32% compared to 2023.
Mellozzan® in the UK is expected to be expanded with the oral solution in 2026. The application is currently under review by the UK Medicines Agency.
About Mellozzan®
Mellozzan® contains the sleep hormone melatonin and is indicated for children with ADHD and sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan® is also indicated for the short-term treatment of jet lag in adults.
About Medice
Medice Arzneimittel Pütter GmbH & Co. KG, founded in 1949 and headquartered in Iserlohn (Germany), is a fully integrated pharmaceutical company with its own GxP capabilities in the development, manufacturing and pan-European and international distribution of pharmaceuticals and medical devices. It is the core of the "Medice - The Health Family" which aims to improve patient care by offering high-quality innovative pharmaceuticals, non-pharmacological interventions and value-added services. For more information, please visit www.medice.com.
For more information contact:
Axel Schörling,
CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com
Bifogade filer